Saturday 30 November 2013

Reportstack Year End Offers on Market Research Reports

Reportstack has announced multiple offers as part of End of Year deals. 
1. Pharma Country Series Bundle Offers

      -  Buy Entire country set and get 50% off
      -  Buy any 3 countries and get 35% off
      -  Buy one country and get 20% off
To know the reports included in this bundle offer please visit http://www.reportstack.com/product/146806/reportstack-year-end-offers-on-pharma-country-series-reports.html for details.
2. Reportstack Pipeline Review Reports- HI 2013 & H2 2013 Offer

Buy 1 get another for half price.

3. 200+ Oil &Gas, Power & Alternative Energy, Nuclear Energy, Clean Technology, Chemicals, Technology and Mining Industry Reports for $8000

4. To know other offers please visit
Contact:
Debora White
Online Marketing Executive
Email: contactus@reportstack.com
Phone: +1-888-789-6604
http://www.reportstack.com






PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update


Reportstack has announced a new market report on PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

US physicians surveyed for this report state that they may follow guidelines such as ACR, but also follow their own clinical experience to treat patients. In the US, about 75% of patient referrals come from Primary Care Physicians (PCPs). Also, most patients who are referred present with signs and symptoms of moderate to severe RA. People seeking treatment are generally in the 55 and older age group. Within this age group, females outnumber men by a small margin.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the United States including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in United States from 2011 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the United States rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in the United States
- Obtain sales forecast from 2011-2022 in the United States


To view the table of contents and know more details please visit PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update report. 

Similar Reports:

PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

The report expects the PsO pipeline to begin launching hopefuls in 2015, starting with Novartis’ secukinumab and Celgene’s apremilast. The following year, Merck’s MK-3222, Lilly’s ixekizumab, Pfizer’s Xeljanz, and Amgen’s brodalumab will emerge, thus jamming the PsO market and making it difficult for each drug to gain market share.

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Psoriasis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the UK.

To view the table of contents and know more details please visit PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

The US is the largest PsO market, although it does not have the highest prevalence of the disease. The report estimates that the US generated approximate sales in 2012. J&J’s Stelara has been impressive since launching in 2009, and claimed close the patient share compared with its company counterpart, Remicade, which only drew less in 2012. Since Stelara’s cost per day is the highest of the biologics, which is three times that of Remicade, it did not take a lot of patient share to generate comfortable annual sales close in 2012.

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Psoriasis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the US.

To view the table of contents and know more details please visit PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

The US is the largest MS market due to the high prevalence of the disease and comparatively high MS drug prices.During the forecast period, the major driver for market growth is an increase in the diagnosis rate following adoption of the revised 2010 McDonald criteria, which greatly reduced the time to diagnosis, and the push by physicians for the earlier initiation of treatment in patients. Other important drivers include the launch of several pipeline DMTs that provide improved efficacy and convenient administration, as well as increased accessibility to treatment due to US healthcare reform, which will both result in higher treatment rates. Furthermore, the launch of novel DMTs that specifically target progressive MS, such as masitinib and siponimod, will also increase treatment uptake by patients with PPMS or SPMS. With several key patent expiries of leading branded products occurring throughout the forecast period, generic erosion will be the biggest barrier to market growth.

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Multiple Sclerosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US

To view the table of contents and know more details please visit PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

MS has a low prevalence in India, which could be due to genetics or environmental factors. However, many physicians surveyed for this report mostly use the Poser criteria to diagnose patients, given the lack of current accessibility to sensitive diagnostic tools, such as MRI. Therefore, it is possible that the current rate of MS in India is grossly underestimated, meaning a large proportion of undiagnosed MS patients are not captured and provided adequate treatment. The major drivers of growth in this market will be the launch of oral DMTs and an increase in availability of advanced diagnostic tools, which will likely lead to increased diagnosis and treatment rates over the forecast period.

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India Multiple Sclerosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India.

To view the table of contents and know more details please visit PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease._x000D_

Aricept is a home-grown product in Japan, and Eisai offers its highest-selling product in additional dosage forms and strengths, which may contribute its rising sales figures. Arimenda will be the first pipeline product to reach the Japanese market and will sustain modest sales throughout the forecast period due to competition from the launch of novel products.

Scope

- Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for the top drugs in Japan from 2012-2022._x000D_
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Alzheimer’s Disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of drug performance _x000D_
- Obtain sales forecast for drugs from 2012-2022 in Japan.


To view the table of contents and know more details please visit PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease._x000D_

Being the most populated nation in the world and having a government with ample resources, China could potentially observe astounding AD drug growth during the forecast period. Unfortunately, we do not envision this to occur within the next 10 years due to China’s acceptance of its underdeveloped healthcare infrastructure. The lack of access to healthcare in rural parts of the nation, the limited provision of social services, and limited efforts to maintain adequate public health suggest that there are many areas that require significant changes before the topic of AD can be properly addressed.

Scope

- Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for the top drugs in China from 2012-2022._x000D_
- Analysis of the impact of key events as well the drivers and restraints affecting China Alzheimer’s Disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of drug performance _x000D_
- Obtain sales forecast for drugs from 2012-2022 in China


To view the table of contents and know more details please visit 

Similar Reports:

PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022. The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years.  However, the market entry of entry of Novartis’ LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the drug’s efficacy in patients with heart failure with preserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drug to show efficacy in this largely underserved patient population. In addition, increased use of MRAs over the forecast period in all seven major markets (7MM) will contribute to the increase in the global CHF market size.

The report estimates that this growth in the French CHF market will be the result of the market entry of a novel treatment, LCZ-696, and an increase in use of MRAs over the forecast period. LCZ-696 has the potential to replace ACE inhibitors in the treatment of CHF. LCZ-696 is a combination drug with Diovan as one of its ingredients; therefore, it is reasonable to expect that LCZ-696 will also steal patient share from Diovan and other ARBs, which are given to patients who cannot tolerate ACE inhibitors.

Scope

- Overview of CHF including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting France CHF market

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CHF
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in France.


To view the table of contents and know more details please visit PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

Thursday 28 November 2013

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Reportstack has announced a new market research publication on China Large Volume Parenteral (LVP) Industry Report, 2013-2015. Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China’s injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.

Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.

Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.

Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.

Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.

The report highlights the followings:

- Status quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
- Status quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
- Operation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.

To view the table of contents and know more details please visit China Large Volume Parenteral (LVP) Industry Report, 2013-2015.

Next Generation Network OSS/BSS Market and Forecast 2013-2018

Reportstack has announced a new market report on Next Generation Network OSS/BSS Market and Forecast 2013-2018. NGN promises a high quality end-user experience. Telecommunications service providers expect the NGN framework to provide them with tools that would ensure customer loyalty.
However, the path towards achieving the ideal NGN is fraught with formidable challenges. The most critical challenge confronting operators is optimizing their OSS and BSS platforms, systems, and processes.

With research beginning in 2007, the report Next Generation Network OSS/BSS Market and Forecast 2013-2018 provides a comprehensive analysis of drivers and issues related to technical and business aspects of OSS/BSS deployments and developments while forecasting their growth over the next five years.

Questions answered in this report include:

•    What are the telecom network operator interests in NGN OSS/BSS?
•    What are the challenges to OSS and BSS implementation?
•    What are the best OSS and BSS approaches for NGN?
•    What are the technologies involved in OSS and BSS?
•    Who are the leading vendors for NGN OSS/BSS?
•    What is the market forecast for OSS and BSS?

The Companies mentioned in this Report are: 013 Netvision, 3 (Hutchison), AAPT, Airtel, Albacom, Alcatel-Lucent, Ascom Network, Testing, Alltel, Alvarion USA, Amdocs, Annies, Antel Uruguay, AOL, Apple, ARTelecom, Ascom, AT & T Dobson, AT & T Edge, AT & T Mobility, AT&T, AT&T Wireless, Augere, AWCC, Axtel Comcel (Voilà), Baikal Westcom Russia, BakCell Azerbaijan, Bandwidth.com, Batelco, Batelco Bahamas, Bell, Bell Aliant, Bell Canada, BellSouth, Communications, Bezeq, Bharti Tele-Ventures, Bouygues Telecom, Brasil Telecom, British Telecom, Broadview, Brocade,BskyB (EasyNet), BSNL, BT, BT Wholesale, Cable & Wireless, CableVision, Caiway, Camtel Cameroon, CAN, CAN Melita, etc.,.

Key Findings: 
Consolidated OSS revenue will realize 1.4 times more than BSS throughout the period
Combined NGN OSS/BSS market (software revenue) will reach US$ 54.36 billion globally in 2018 with 13.72% CAGR
From component perspective, share of services revenue will increase from a little above 40% to 60% of totals by 2018
NA will remain be the top revenue generating zone with 39% market share and APAC will follow with fastest CAGR of 16.82%
An OSS platform shift will be triggered by wearable devices(wearable glasses, smartwatch, etc.) and cloud service medium for BSS
Among five OSS modular markets, PSA will have the highest market share by 33% but IM will experience the fastest CAGR of 22.14%
Report Benefits: 
Technical Overview of OSS and BSS in NGNs: This section begins with an introduction to OSS and BSS and their roles in the operator environment. It explains the various blocks that go into building of the OSS: Network elements, events, alarms and others. It next explains the BSS building blocks: Billing, rating, mediation, charging, customer care and others. This section is followed by the description of prevalent industry approaches like TMN - FCAPS model that are widely followed by operators. The section then analyzes the technical impact of NGN on OSS and BSS architectures.
Vendor Analysis: Profiles of vendors offering OSS/BSS products and services for next generation networks. This section first explains the basis of vendor selection including vendor classification, innovative contribution, market leadership position and future growth path. Each vendor is then analyzed in the light of its product and solution portfolio, major implementations, differentiating aspects with other vendors and their future plans. The report includes recommendations to vendors including diversification, best practices, market segment, and solution approach.
Quantitative Analysis and Forecast: This section begins with a detailed explanation of the research methodology. Quantitative analysis includes measurable items such as billing systems, network management systems and their sub-classes (mediation, wholesale billing, retail billing, CRM, revenue assurance, resource management, task management, delivery management, synchronization management) along with geographical segmentation, trends and projections. Importantly, the quantitative analysis assesses the impact of various drivers and issues on the above measurable items, thus forming a logical conclusion of the quantitative discussion in the previous sections. NOTE: This section represents a comprehensive forecast including Forecast Methodology by Overall OSS and BSS Software Market, Split by OSS and by BSS separately, by geography (NA, EMEA, CALA, and APAC), and by modular break-up including: Network Planning and Engineering (NPE), Fault Management (FM), Performance Management (PM), Provisioning and Service Activation (PSA), Inventory Management (IM), Billing and Customer Care (B&CC), Mediation (MD), and Revenue Assurance (RA).
To view the table of contents and know more details please visit Next Generation Network OSS/BSS Market and Forecast 2013-2018 report.

The Network Functions Virtualization (NFV) Market: Business Case, Market Analysis and Forecasts 2014 - 2019

Reportstack has announced a new market report on The Network Functions Virtualization (NFV) Market: Business Case, Market Analysis and Forecasts 2014 - 2019. Network Functions Virtualization (NFV) is a telecom led initiative that aims to utilize standard IT virtualization technology to consolidate many telco network equipment types onto industry standard high volume servers, switches and storage. NFV involves implementing network functions in software that can run on a range of industry standard server hardware, and that can be moved to, or instantiated in, various locations in the network as required, without the need to install new proprietary equipment.
With a promise to drive significant CapEx and OpEx reductions, NFV is poised to transform the entire telco infrastructure ecosystem. The report  estimates that global spending on NFV solutions will grow at a CAGR of 46% between 2014 and 2019. NFV revenues will reach $1.3 Billion by the end of 2019. This report provides an in-depth assessment of the global NFV market, including a study of the business case, technology, use cases, vendor landscape, and a quantitative assessment of the industry from 2014 to 2019.

The addresses the following key topics:

• Key Issues in NFV: An assessment of key issues related to NFV
• NFV Use Cases: A review of specific use cases for the Big Data market
• NFV Technology: A review of the underlying technologies that enable NFV
• The Business Case for NFV: An assessment of the business case, growth drivers and barriers for NFV
• Vendor Assessment: An assessment of the vendor landscape of leading players within the NFV market
• Market Analysis and Forecasts: A global and regional assessment of the market size and forecasts for the NFV market from 2014 to 2019

Target Audience: 
SDN providers
Mobile network operators
Telecom infrastructure providers
Cloud and virtualized datacenters
NFV technology/solution vendors
Telecom service providers of all types
Digital content and application providers
The Companies in Report are: Amazon, Azuze, AT&T, 6WIND, Alcatel-Lucent, Amdocs, BT, CIMI Corp, Cisco, Connectem, ConteXtream, Ericsson, F5, Google, Huawei, Intel, Juniper Networks, Meraki, NEC, NSN, Openwave Mobility
Oracle, Skyfire/Opera, Telefonica.

Key Findings: 
Early NFV deployments will target virtualization of the mobile core (EPC) and IMS services
NFV IaaS will open a major opportunity for data center and cloud service providers to play a greater role in the telco services market
Mind Commerce estimates the NFV market to be worth $203 Million in 2014. Growing at a CAGR of 46 % between 2014 and 2019, NFV revenues will reach $1.3 Billion by the end of 2019
Companies with expertise in network virtualization technology as well as commodity hardware manufacturers such as Intel will significantly benefit from the commercialization of NFV

To view the table of contents and know more details please visit The Network Functions Virtualization (NFV) Market: Business Case, Market Analysis and Forecasts 2014 - 2019 report.

Global and China CMOS Camera Module Industry Report, 2013

Reportstack has announced a new market research publication on Global and China CMOS Camera Module Industry Report, 2013 which involves the followings:

1, Brief introduction to the CMOS camera module industry
2, CMOS camera module market research
3, Analysis on CMOS imager sensor vendors
4, Analysis on lens vendors
5, Analysis on CCM vendors

The growth rate of cell phone camera pixels slows down, or even declines in 2013. Apple's iPhone 5S still employs 8-megapixel, instead of 13-megapixel adopted by other top cell phone vendors. In addition, several Chinese star models such as MEIZU's MX3 and BBK's Vivo X3 also have the respective resolution of 8-megapixel, indicating that the competition may shift from pixel value to pixel size. MX3 is equipped with Sony IMX179 Sensor and has the pixel size of 1.4μm; Vivo X3 is installed with Samsung 3H7 Image Sensor and has the same pixel size as MX3.

HTC ONE utilizes ST's VD6869 sensor chip with the pixel size of 2.0μm which was called as Ultral Pixel. Unless a 13-megapixel sensor with a greater pixel size is launched, Apple may also adhere to 8-megapixel.

Subject to the insufficient capacity of cell phone optical image stabilizers (OIS), Samsung does not launch OIS-enabled phones in 2013, but it will make S5 model equipped with OIS in 2014. HTC (one), SONY (Xperia ZU), LG (G2 flagship) and Google (Nexus5) are all installed with OIS. Samsung’s S5 to be launched in 2014 will greatly accelerate the popularity of OIS, and Samsung's OIS provider HYSONIC expects to see the growth rate of over 300% in its revenue in 2014.

The Tablet PC shipment has shown the signs of touching the ceiling, and its future growth will be sluggish.

Mid-size and luxury cars are sold well in China, which makes the automotive CCM market become the most potential market. For example, KIA's K9 uses five sets of CCM. The automotive CCM shipment totaled 24,946,000 sets in 2012 and will grow by 56.4% year on year to 39,008,000 sets in 2013. The shipment is expected to maintain rapid growth, reaching 59,632,000 sets with the increase of 52.9% in 2014. The automotive CCM market is dominated by Panasonic, Sony, Magna, Valeo, MCNEX, Gentex, Fujitsu, Continetal and Autoliv.

Without taking DSC into account, CMOS camera modules generate the output value of about USD13 billion in 2013, up 28.7% from 2012. The output value is expected to hit USD15.9 billion in 2014, representing a year-on-year increase of 22.3%, mainly because of the adding of higher pixels and more complex features such as OIS.

At the image sensor market, Omnivision, Samsung and Sony compete with each other fiercely. Sony firmly occupies the high-end market, especially the market of 13MP and bigger pixel size; Omnivision's revenue in FY2013 surged by 56.8% from the figure in FY2012 by virtue of low prices, but with profit sacrifice. Aptina transfers to less competitive non-handset markets, and sold all assets of Italy Avezzano Semiconductor Plant.

As for the lens field, Largan ranks first, far ahead of the second follower. Largan almost monopolizes the beyond-8-megapixel lens market. Its gross margin and operating margin jump from 2012 and the revenue is approaching USD1 billion. The revenue of the second-ranked GSEO falls to less than USD350 million in 2013.

In the field of modules, Nokia's shipment decline has made its suppliers suffer from income losses, including Foxconn, Sharp, STMICRO and KMOT. KMOT has contracted the module business and may exit from this area. Taiwanese vendors LITEON, PRIMAX and CHICONY are facing weak growth. However, Chinese and South Korean vendors are developing triumphantly, especially South Korea ones. LG INNOTEK has achieved the world's first laureate again, mainly serving Apple whose at least 70% CCM comes from LG INNOTEK. Taiwanese vendors can only snatch Apple's orders for low-end products. SEMCO's revenue soars thanks to Samsung's handset shipment surge; by profit, SEMCO acts as the world's largest CCM vendor.

Among Chinese mainland vendors, SUNNY witnesses the strongest growth, and its shipment in 2013 is expected to reach 136 million units, doubling that in 2012. Besides, South Korean vendors also push aggressively into Chinese market, for instance, MCNEX is ZTE's largest supplier and Cowell acts as Lenovo's supplier.

To view the table of contents and know more details please visit Global and China CMOS Camera Module Industry Report, 2013 

Wednesday 27 November 2013

Wind Turbine Service Market in Europe 2014-2018

Reportstack has announced a new market report on Wind Turbine Service Market in Europe 2014-2018 which forecasts that the market is expected to grow at a CAGR of 9.02 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in aging wind farms. The Wind Turbine Service market in Europe has also been witnessing the increase in investments by OEMs. However, the lack of skilled workforce could pose a challenge to the growth of this market.

The Wind Turbine Service Market in Europe 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Wind Turbine Service market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Enercon GmbH, GAMESA CORPORACIÓN TECNOLÓGICA, S.A, Nordex SE, Repower System AG, and Siemens AG.

Other vendors mentioned in the report are GE Energy LLC, Suzlon Energy Ltd, The Weir Group PLC, Vestas Wind Systems A/S, and Windtechnics.

Key questions answered in this report:

What will the market size be in 2018 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

To view the table of contents and know more details please visit Wind Turbine Service Market in Europe 2014-2018 report.